Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Inclusion Criteria: * Diagnosis of AD via simplified UK Working Group Criteria and a baseline PSGA score of 2 or greater * Willingness to adhere to study protocol * Subjects taking hormone-containing medications must be on a stable dose for 6 months prior to study start to avoid any confounding influence on sensory and pain perception Exclusion Criteria: * Use of topical or oral anti-inflammatory medications for 2 weeks prior to the study start. * Use of topical or oral anti-histamines for 2 weeks prior to the study start (as rescue medication allowed). * Use of topical or oral anti-pruritic agents for 2 weeks prior to the study start. * Use of oral neuromodulatory agents for 2 months prior to study start. * Current use of chronic pain medications (including opioids, antidepressants and anti-epileptic drugs). * Use of nicotine-containing products for the past 6 months prior to study start. * History of radiation or chemotherapy. * History of traumatic injury on prospective test sites. * Unstable thyroid function within the past 6 months prior to study start to exclude thyroid-related neuropathy * Known history of central or peripheral nervous system dysfunction. * History of acute hepatitis, chronic liver disease or end stage liver disease. * History of human immunodeficiency virus (HIV) or acquired immune deficiency syndrome. * History of neuropathy associated with chronic obstructive pulmonary disease, diabetes mellitus, documented exposure to organophosphates or heavy m…